Glenmark Pharma receives USFDA nod for skin lotion
New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for Desonide lotion used to treat skin rashes and irritation.
"Glenmark Pharmaceuticals has been granted final approval by the United States Food and Drug Administration (USFDA) for Desonide lotion, 0.05 percent," the company said in a regulatory filing.
According to IMS Health sales data, for the 12 months ended July, the Desonide lotion, 0.05 percent, achieved annual sales of around USD 23.2 million, Glenmark said.
The company's current portfolio consists of 126 products authorized for distribution in the US market and 61 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd